Recent advancements in Cancer Targeting Therapy with the Hyaluronic Acid as a Potential Adjuvant.
- Published in:
- Ars Pharmaceutica, 2022, v. 63, n. 4, p. 387, doi. 10.30827/ars.v63i4.25208
- By:
- Publication type:
- Article
Works matching IS 00042927 AND DT 2022 AND VI 63 AND IP 4
Results: 7
1
2
Liposomas en el desarrollo de formas farmacéuticas semisólidas.
- Published in:
- Ars Pharmaceutica, 2022, v. 63, n. 4, p. 372, doi. 10.30827/ars.v63i4.26059
- By:
- Publication type:
- Article
3
Intensificación de Ustekinumab en enfermedad de Crohn: Revisión sistemática.
- Published in:
- Ars Pharmaceutica, 2022, v. 63, n. 4, p. 345, doi. 10.30827/ars.v63i4.24740
- By:
- Publication type:
- Article
4
Quitosano de Cangrejos con actividad antimicrobiana en compotas artesanales de plátanos.
- Published in:
- Ars Pharmaceutica, 2022, v. 63, n. 4, p. 335, doi. 10.30827/ars.v63i4.25982
- By:
- Publication type:
- Article
5
Momordica charantia extract modulates inflammatory response in human lymphocytes via suppression of TNF-α.
- Published in:
- Ars Pharmaceutica, 2022, v. 63, n. 4, p. 320, doi. 10.30827/ars.v63i4.24256
- By:
- Publication type:
- Article
6
Clinical practice in prevention of migraine with calcitonin-gene related peptide monoclonal antibodies: real-world evidence.
- Published in:
- Ars Pharmaceutica, 2022, v. 63, n. 4, p. 311, doi. 10.30827/ars.v63i4.23848
- By:
- Publication type:
- Article
7
Nutrición parenteral suplementada en el final de la vida: consideraciones nutricionales y tecnológicas.
- Published in:
- Ars Pharmaceutica, 2022, v. 63, n. 4, p. 355, doi. 10.30827/ars.v63i4.25339
- By:
- Publication type:
- Article